Company Overview - Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases [3] - The company leverages expertise in medicinal chemistry, structural biology, and immunology to discover differentiated oral small molecule therapeutics for conditions with high unmet medical need [3] Product Pipeline - Ventyx's portfolio includes NLRP3 inhibitors such as VTX2735, which is in Phase 2 development for recurrent pericarditis, and VTX3232, a CNS-penetrant NLRP3 inhibitor in Phase 2 development for neurodegenerative and cardiometabolic diseases [4] - The inflammatory bowel disease portfolio features two Phase 2 compounds: tamuzimod (VTX002), an S1P1R modulator, and VTX958, a TYK2 inhibitor [4] Upcoming Events - Company executives will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 5, 2025, from 12:50 to 1:20 PM ET [2] - A webcast of the event will be available on the Ventyx website, with a replay accessible for ninety days post-event [2]

Topline data from multiple Phase 2 studies expected throughout 2025 • Q2 readout from VTX3232 study in patients with early Parkinson’s disease • H2 readout from VTX2735 study in patients with recurrent pericarditis • H2 readout from VTX3232 study in participants with obesity and cardiometabolic risk factors Cash, cash equivalents and marketable securities balance of $228.8M as of March 31, 2025 expected to fund planned operations into at least H2 2026 SAN DIEGO, May 08, 2025 (GLOBE NEWSWIRE) -- Ventyx Bio ...

Core Insights - Ventyx Biosciences has appointed seven internationally recognized experts to its Scientific Advisory Board (SAB), enhancing its leadership in the NLRP3 inflammasome research and development [1][2][3] Group 1: Appointment of SAB Members - The new SAB members have significant expertise in NLRP3 inflammasome research and its implications in neurodegenerative and cardiometabolic diseases [2][3] - The expanded SAB will provide guidance in the clinical development of Ventyx's oral NLRP3 inhibitors, particularly in Phase 2 studies for Parkinson's disease and other conditions [3][4] Group 2: Company Development and Research Focus - Ventyx is focused on developing innovative oral therapies for autoimmune, inflammatory, and neurodegenerative diseases, leveraging its expertise in medicinal chemistry and immunology [11][12] - The company is advancing two lead NLRP3 inhibitors, VTX2735 and VTX3232, through Phase 2 trials, with topline data for VTX3232 in Parkinson's disease expected in Q2 2025 [4][12]